严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行对前列腺癌诊断的影响
Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer.
作者信息
Oppolzer Immanuel A, Schnabel Marco J, Hammer Selma, Zilles Hannah, Haas Maximilian, Goßler Christopher, Müller Maximilian R, Burger Maximilian, Gierth Michael
机构信息
Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
出版信息
Urol Int. 2025;109(2):158-166. doi: 10.1159/000541753. Epub 2024 Oct 3.
INTRODUCTION
The aim of this study was to prove if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC).
METHODS
A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2 pandemic and 14 months preceding it.
RESULTS
Nine hundred sixty-nine men prior (T0) and 1,343 during the pandemic (T1) were included. Mean age was 68.0 (SD 8.2). Median initial prostate-specific antigen was 8.1 ng/mL (T0) and 7.9 ng/mL (T1, p = 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p = 0.001), to staging (T0: 1.1 months vs. T1: 0.75 months, p = 0.707), and to therapy (T0: 3.0 months vs. T1: 2.0 months, p < 0.001) was shortened during the pandemic. Classified by d'Amico, a significant shift toward higher risk groups was seen (p = 0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3% to 8.9% (p = 0.433). Pathological staging showed pT3+ in 44.4% versus 44.7% (p = 0.565) and pN+ in 9.9% versus 9.6% (p = 0.899).
CONCLUSION
Regarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2 pandemic.
INTRODUCTION
The aim of this study was to prove if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC).
METHODS
A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2 pandemic and 14 months preceding it.
RESULTS
Nine hundred sixty-nine men prior (T0) and 1,343 during the pandemic (T1) were included. Mean age was 68.0 (SD 8.2). Median initial prostate-specific antigen was 8.1 ng/mL (T0) and 7.9 ng/mL (T1, p = 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p = 0.001), to staging (T0: 1.1 months vs. T1: 0.75 months, p = 0.707), and to therapy (T0: 3.0 months vs. T1: 2.0 months, p < 0.001) was shortened during the pandemic. Classified by d'Amico, a significant shift toward higher risk groups was seen (p = 0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3% to 8.9% (p = 0.433). Pathological staging showed pT3+ in 44.4% versus 44.7% (p = 0.565) and pN+ in 9.9% versus 9.6% (p = 0.899).
CONCLUSION
Regarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2 pandemic.
引言
本研究的目的是证实严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行是否导致前列腺癌（PC）的诊断和治疗延迟。
方法
在一所大学癌症中心进行了一项单中心回顾性分析。纳入了2019年1月至2021年12月期间诊断为未经治疗的PC的所有患者。观察涵盖了SARS-CoV-2大流行的22个月及其之前的14个月。
结果
纳入了大流行前（T0）的969名男性和大流行期间（T1）的1343名男性。平均年龄为68.0（标准差8.2）。初始前列腺特异性抗原的中位数在T0时为8.1 ng/mL，在T1时为7.9 ng/mL（p = 0.288）。在大流行期间，从活检到肿瘤委员会（T0：1.3个月对T1：0.9个月，p = 0.001）、到分期（T0：1.1个月对T1：0.75个月，p = 0.707）以及到治疗（T0：3.0个月对T1：2.0个月，p < 0.001）的时间缩短了。根据达米科分类，观察到向更高风险组有显著转变（p = 0.024）。局部分期显示局部晚期PC略有增加。转移性疾病从10.3%降至8.9%（p = 0.433）。病理分期显示pT3 + 分别为44.4%对44.7%（p = 0.565），pN + 分别为9.9%对9.6%（p = 0.899）。
结论
关于PC的诊断和治疗，我们无法证实SARS-CoV-2大流行导致了任何延迟。
引言
本研究的目的是证实严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行是否导致前列腺癌（PC）的诊断和治疗延迟。
方法
在一所大学癌症中心进行了一项单中心回顾性分析。纳入了2019年1月至2021年12月期间诊断为未经治疗的PC的所有患者。观察涵盖了SARS-CoV-2大流行的22个月及其之前的14个月。
结果
纳入了大流行前（T0）的969名男性和大流行期间（T1）的1343名男性。平均年龄为68.0（标准差8.2）。初始前列腺特异性抗原的中位数在T0时为8.1 ng/mL，在T1时为7.9 ng/mL（p = 0.288）。在大流行期间，从活检到肿瘤委员会（T0：1.3个月对T1：0.9个月，p = 0.001）、到分期（T0：1.1个月对T1：0.75个月，p = 0.707）以及到治疗（T0：3.0个月对T1：2.0个月，p < 0.001）的时间缩短了。根据达米科分类，观察到向更高风险组有显著转变（p = 0.024）。局部分期显示局部晚期PC略有增加。转移性疾病从10.3%降至8.9%（p = 0.433）。病理分期显示pT3 + 分别为44.4%对44.7%（p = 0.565），pN + 分别为9.9%对9. 6%（p = 0.899）。
结论
关于PC的诊断和治疗，我们无法证实SARS-CoV-2大流行导致了任何延迟。
Zotero 插件